XVir Therapeutics

Executive Summary

XVir Therapeutics GmbH is a German biopharmaceutical company pioneering oncolytic immunotherapy through its proprietary YB-1 dependent oncolytic adenoviruses. Founded in 2019 and headquartered in Munich, the company leverages a novel mechanism that selectively lyses tumor cells while inducing a systemic anti-cancer immune response. This dual action positions XVir to address key limitations of conventional oncolytic therapies, including poor tumor penetration and insufficient immune activation. Despite being in early stages (preclinical or Phase I), the platform's unique dependency on the YB-1 transcription factor, which is overexpressed in many cancers, offers a broad therapeutic window and potential for combination with checkpoint inhibitors. The company operates in the competitive viral immunotherapy space but differentiates via its tumor-selective replication and immune-stimulatory profile. Key risks include early-stage development challenges, manufacturing complexity for adenoviral vectors, and limited visibility into clinical timelines. However, XVir's focus on a validated target (YB-1) and established modality (oncolytic viruses) provides a credible path to clinical validation.

Upcoming Catalysts (preview)

• Q3 2026Initiation of first-in-human clinical trial for lead candidate XVir-00165% success
• Q2 2026Publication of preclinical proof-of-concept data in peer-reviewed journal80% success
• Q4 2026Strategic partnership or licensing deal for oncology combination therapy40% success